DNAG.OB

[invol_inlf]

Today's range, it is trying to breakout.  Lots of news lately:
http://finance.yahoo.com/q?s=DNAG.OB

[invol_inlf]

Looking good.

http://biz.yahoo.com/iw/060314/0112989.html

[akclide]

Crossed it's .03 resistance,next res is at .04.

[kidneydr]

big big news....it is going to move big...compound more potent than epo

[kidneydr]

erythropoeitin sales are big money maker

[kidneydr]

amgen profits based on epo sales

[invol_inlf]

amgen profits based on epo sales

DNAPrint Announces Discovery of Genetic Marker for Statin-Induced Myalgia
Tuesday December 19, 7:00 am ET


Findings From Company's Statnome Project Successfully Validated; Article on Study to Be Published in Noted Academic Journal


SARASOTA, FL--(MARKET WIRE)--Dec 19, 2006 -- DNAPrint Genomics, Inc. (OTC BB:DNAG.OB - News), today announced that the Company's research staff has discovered a genetic marker for statin-induced myalgia (chronic muscle pain), that a patent has been filed to protect the discovery and that the research on which the discovery is based will be published in an upcoming issue of The Journal of Pharmacogenetics and Genomics (JPG).

The marker was the primary discovery from the Company's Statnome project initiated in 2000 and the manuscript to be published in JPG describes the validation of this finding in different patient samples.

"Myalgia or chronic muscle pain is a common side effect reported by patients who take statins for cholesterol control, and it is likely to be part of a disease continuum that includes myositis and rhabdomyolysis, which is a breakdown of muscle fibers that frequently results in kidney damage and is a potentially fatal side-effect," according to DNAPrint Chief Science Officer Tony Frudakis, Ph.D. "Deaths associated with statin-induced rhabdoymyolysis lead Bayer to withdraw Cerivistatin in 2001. We are satisfied to have brought one of our first pharmacogenetics programs full circle from discovery through validation and we consider the R&D phase for this project complete. With the filing of a patent to protect this discovery, the Company will be able to develop a proprietary test for this gene variant and thereby reduce the likelihood of illness or death in those patients who are taking statins. This study also criticizes the original clinical trials for statins, which did not fully or adequately explore the relationship between statins and myalgia or even rhabdomyolysis."

"This is the culmination of a project that was begun when the company was founded," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "It has taken until now to validate the original findings, but validated they are. The Company has filed a patent to protect this process. We plan to bring to market a definitive test product to identify this genetic variant and to potentially prevent painful -- and in some cases, fatal -- side effects in thousands of patients who are taking a very common prescription drug."

DNAPrint's study of 750 patients who had taken either atorvastatin (Lipitor®) or simvastatin (Zocor®) showed that patients carrying one specific genetic marker were approximately 2.5 times more likely to experience mild to severe muscle pain (myalgia). The effect was most pronounced for atorvastatin and the study showed that approximately one half of the patients who were removed from atorvastatin therapy due to muscle symptoms possess this genetic marker, whereas in the general population (with and without cardiovascular disease) only approximately 15%-25% of people carry the marker. DNAPrint applied its technology for measuring population structure (e.g., ancestry) in order to prove that the finding in both the discovery and validation samples was genuine, and in so doing received praise from JPG reviewers. This observation indicates that the genetic marker may be related not only to response to statins but also to a possible relationship with higher cholesterol levels, according to the study.

"DNA Print Genomics was founded on the underlying genomic screening methods developed to more efficiently scan the genome for medically important genetic markers of drug responses," stated Dr. Frudakis. "The current findings are another example of the efficiency of the Company's methods."

[buffaholic]

We've got to get by this .0175 level and then we could be off to the races. Volume needs to pick up though.

[buffaholic]

Partnering with the fine people at Code Amber (Amber Alerts). Wonder if this will get this thing past the .0175 level. That's been some stiff resistence for this thing.

[buffaholic]

Finally got past resistence although I wish volume was a bit higher. Could get interesting from here.

[buffaholic]

Filed this 8k. They sold much of their stake in Biofrontera. Could get a pop depending on how they choose to spend the money.

http://biz.yahoo.com/e/070305/dnag.ob8-k.html

[horwel]

http://www.bradenton.com/mld/bradenton/business/16502822.htm


Both Gomez and DNAPrint Genomics will also be part of a massive research initiative announced last month by the H. Lee Moffitt Cancer Center & Research Institute of Tampa. The center said it would partner with an affiliate of Merck & Co., Inc. pharmaceutical company to expand biotechnology research with the goal of developing personalized medicine.

Merck and Moffitt will form a for-profit company, called M2GEN, that will develop personalized cancer treatments using a patient's genetic profile.




City Vote for M2GEN founding is on the 15th,State and county are approved.

Looks good....

[horwel]

Next week could get interesting...

[buffaholic]

I like the chart. It's set up for a nice run, especially since the city council votes this week on the M2GEN funding. DNAG is said to be involved with Merck. I emailed the company and they basically told me more info would be made available after the vote. Good luck.